Sana Biotechnology Files 8-K on Operations & Financial Condition
Ticker: SANA · Form: 8-K · Filed: 2024-02-07T00:00:00.000Z
Sentiment: neutral
Topics: financial-condition, operations, 8-K, corporate-update
TL;DR
**SANA just dropped an 8-K with fresh financials, time to check their numbers!**
AI Summary
Sana Biotechnology, Inc. filed an 8-K on February 7, 2024, to report on its results of operations and financial condition, along with other events. This filing, under SEC File Number 001-39941, indicates that the company is providing updated financial information. For investors, this matters because it offers a current snapshot of the company's financial health, which can influence stock performance and future investment decisions.
Why It Matters
This filing provides investors with the latest financial and operational updates from Sana Biotechnology, Inc., crucial for assessing the company's performance and making informed investment choices.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial and operational updates, not indicating any immediate high-risk events.
Analyst Insight
Investors should review the full details of the 'Results of Operations and Financial Condition' once available to understand the specific financial updates and their potential impact on Sana Biotechnology, Inc.'s valuation.
Key Players & Entities
- Sana Biotechnology, Inc. (company) — the registrant filing the 8-K
- February 7, 2024 (date) — date of earliest event reported and filing date
- 001-39941 (string) — SEC File Number for Sana Biotechnology, Inc.
- Delaware (string) — state of incorporation for Sana Biotechnology, Inc.
- Nasdaq Global Select Market (string) — exchange where Sana Biotechnology's Common Stock is registered
FAQ
What is the purpose of Sana Biotechnology, Inc.'s 8-K filing dated February 7, 2024?
The 8-K filing by Sana Biotechnology, Inc. on February 7, 2024, is intended to report on the company's 'Results of Operations and Financial Condition' and 'Other Events,' as indicated by the 'ITEM INFORMATION' sections in the filing.
What is the trading symbol and the exchange where Sana Biotechnology, Inc.'s common stock is registered?
Sana Biotechnology, Inc.'s common stock trades under the symbol 'SANA' and is registered on 'The Nasdaq Global Select Market,' as stated in the 'Securities registered pursuant to Section 12(b) of the Act' section of the filing.
What is the business address and phone number of Sana Biotechnology, Inc. as listed in the filing?
The business address for Sana Biotechnology, Inc. is '188 East Blaine Street, Suite 400, Seattle, Washington 98102,' and its telephone number is '(206) 701-7914,' according to the 'BUSINESS ADDRESS' section.
Is Sana Biotechnology, Inc. considered an emerging growth company according to this 8-K filing?
No, the filing indicates with an unchecked box 'o' next to 'Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933,' meaning Sana Biotechnology, Inc. is not currently designated as an emerging growth company.
What is the Central Index Key (CIK) for Sana Biotechnology, Inc.?
The Central Index Key (CIK) for Sana Biotechnology, Inc. is '0001770121,' as found in the 'COMPANY DATA' section of the filing.
Filing Stats: 1,002 words · 4 min read · ~3 pages · Grade level 15.6 · Accepted 2024-02-07 16:12:56
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share SANA The Nasdaq
- $205.4 million — s of January 2, 2024 were approximately $205.4 million. This estimate of the Company's cash, c
Filing Documents
- d180813d8k.htm (8-K) — 29KB
- d180813dex991.htm (EX-99.1) — 16KB
- g180813g0207153810961.jpg (GRAPHIC) — 29KB
- 0001193125-24-026692.txt ( ) — 216KB
- sana-20240207.xsd (EX-101.SCH) — 3KB
- sana-20240207_lab.xml (EX-101.LAB) — 18KB
- sana-20240207_pre.xml (EX-101.PRE) — 11KB
- d180813d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sana Biotechnology, Inc. Date: February 7, 2024 By: /s/ Bernard J. Cassidy Bernard J. Cassidy Executive Vice President and General Counsel